コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 patient type (with vs without systemic lupus erythematosus).
2 disease in a murine model of systemic lupus erythematosus.
3 f autoimmune diseases such as systemic lupus erythematosus.
4 +) T cells from patients with systemic lupus erythematosus.
5 and are also associated with systemic lupus erythematosus.
6 locytes from individuals with systemic lupus erythematosus.
7 icated in the pathogenesis of systemic lupus erythematosus.
8 flammatory bowel disease, and systemic lupus erythematosus.
9 drome and are associated with systemic lupus erythematosus.
10 autoimmune diseases, such as systemic lupus erythematosus.
11 l hyperactivity, hallmarks of systemic lupus erythematosus.
12 f RAGE in the pathogenesis of systemic lupus erythematosus.
13 rheumatoid arthritis (RA) or systemic lupus erythematosus.
14 iopathic arthritis (SJIA) and systemic lupus erythematosus.
15 ia, rheumatoid arthritis, and systemic lupus erythematosus.
16 ed autoimmunity in a model of systemic lupus erythematosus.
17 nd C1r/C1s deficiencies cause systemic lupus erythematosus.
18 morbidity in patients with systematic lupus erythematosus.
19 ion of the autoimmune disease systemic lupus erythematosus.
20 sis of the autoimmune disease systemic lupus erythematosus.
21 ic susceptibility regions for systemic lupus erythematosus.
22 naling in the pathogenesis of systemic lupus erythematosus.
23 ecently approved for nonrenal systemic lupus erythematosus.
24 of morbidity and mortality in systemic lupus erythematosus.
25 with the autoimmune disorder systemic lupus erythematosus.
26 ucing autoreactive B cells in systemic lupus erythematosus.
27 sttransplant vasculopathy and systemic lupus erythematosus.
28 arthritis and childhood-onset systemic lupus erythematosus.
29 the molecular pathogenesis of systemic lupus erythematosus.
30 nction and is associated with systemic lupus erythematosus.
31 es, rheumatoid arthritis, and systemic lupus erythematosus.
32 s of rheumatoid arthritis and systemic lupus erythematosus.
33 isease activity and damage in systemic lupus erythematosus.
34 isms that are associated with systemic lupus erythematosus.
35 ibody-driven diseases such as systemic lupus erythematosus.
36 its increased production in cutaneous lupus erythematosus.
37 viable therapeutic target in systemic lupus erythematosus.
38 nflammatory bowel disease and systemic lupus erythematosus.
39 of BAFF-targeted therapies in systemic lupus erythematosus.
40 n AA, autoimmune uveitis, and systemic lupus erythematosus.
41 ividuals and in patients with systemic lupus erythematosus.
42 ic mouse model of spontaneous systemic lupus erythematosus.
43 s/PCs in patients with active systemic lupus erythematosus.
44 tracellular innate sensors in systemic lupus erythematosus.
45 , psoriasis (18 [20.9%]), and systemic lupus erythematosus (12 [14.0%]) were the most common autoimmu
46 an the level in patients with systemic lupus erythematosus (1346+/-1011 pg per milliliter), ankylosin
47 ammatory bowel disease, 2 had systemic lupus erythematosus, 2 had multiple sclerosis, 2 had autoimmun
48 es that are characteristic of systemic lupus erythematosus, a chronic autoimmune disease with multipl
50 oid arthritis, multiple sclerosis, and lupus erythematosus, adjusting for age, gender, race, and prim
52 h autoimmune diseases such as systemic lupus erythematosus, Aicardi-Goutieres syndrome (AGS) and fami
53 ed B cells from patients with systemic lupus erythematosus, an autoimmune disorder with a strong fema
54 DLE) is a chronic variant of cutaneous lupus erythematosus, an autoimmune inflammatory disorder of th
56 chloroquine used for treating systemic lupus erythematosus and a Syk inhibitor blocked NA-TLR localiz
57 autoimmune diseases including systemic lupus erythematosus and Crohn's disease, and relevant autoimmu
58 disorders, most particularly systemic lupus erythematosus and dermatomyositis, are also characterize
62 h autoimmune diseases such as systemic lupus erythematosus and neuromyelitis optica, and can lead to
63 ells (PCs), are a hallmark of systemic lupus erythematosus and play a key role in disease pathogenesi
65 ory pathways in two systemic (systemic lupus erythematosus and rheumatoid arthritis) and two organ-sp
70 ated in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy, and preclinical m
72 alpha interferon signature of systemic lupus erythematosus and the interleukin-1 signature in systemi
75 mia (AA), autoimmune uveitis, systemic lupus erythematosus, and sickle cell disease, respectively, as
76 g and common manifestation in systemic lupus erythematosus, and the etiology of this predisposition f
77 s with those in patients with systemic lupus erythematosus, ankylosing spondylitis, and hepatic fibro
78 Goutieres syndrome and severe systemic lupus erythematosus are generally lethal disorders that have b
80 ases rheumatoid arthritis and systemic lupus erythematosus, as well as the spondyloarthropathies whic
83 l role in the pathogenesis of systemic lupus erythematosus, but the underlying mechanisms remain poor
84 nent C3 have been reported in systemic lupus erythematosus, but their molecular mechanism and functio
85 lls play an important role in systemic lupus erythematosus by acting not only as precursors of autoan
86 -Goutieres syndrome (AGS) and systemic lupus erythematosus, can arise when TREX1 function is compromi
87 diabetes, multiple sclerosis, systemic lupus erythematosus, celiac disease, Crohn's disease, Addison'
88 thematosus patient cells, and systemic lupus erythematosus cells with high IFN signature responded we
89 is a rare, autosomal dominant form of lupus erythematosus characterized by cold-induced inflammatory
91 elp exclude disorders such as systemic lupus erythematosus, common variable immunodeficiency, and aut
92 ex-mediated diseases, such as systemic lupus erythematosus, commonly affect the kidney and determine
93 values from all patients with systemic lupus erythematosus correlated positively with systemic lupus
97 these diffusivities with the systemic lupus erythematosus disease activity index are in line with cy
98 us correlated positively with systemic lupus erythematosus disease activity index score (P = 0.033, P
102 ents with prostate cancer and systemic lupus erythematosus exhibit reduced DNase I activity, and pati
103 s obtained from patients with systemic lupus erythematosus exhibited increased CD45 activity and BCR-
106 vestigations of patients with systemic lupus erythematosus have applied insights from studies of the
107 tibody-associated vasculitis, systemic lupus erythematosus, idiopathic pulmonary fibrosis and dengue
108 icated in the pathogenesis of systemic lupus erythematosus in human patients and murine models of lup
109 ndrome and syndromic forms of systemic lupus erythematosus, including familial chilblain lupus and sp
111 uman rheumatoid arthritis and systemic lupus erythematosus, indicating that increased autophagy as a
121 nervous system involvement in systemic lupus erythematosus is common and results in several neurologi
122 he symptoms of the autoimmune disorder lupus erythematosus is not known but may involve a role for th
123 tion of discoid and subacute cutaneous lupus erythematosus lesions showed significant epidermal up-re
125 RIIB-deficient mice develop a systemic lupus erythematosus-like disease at a markedly accelerated rat
128 /autoimmune disorders such as systemic lupus erythematosus; lymphoproliferative disorders such as chr
130 us adverse events (periorbital oedema, lupus erythematosus [occurring twice], erythema, and dermohypo
131 events-periorbital oedema (one [4%]), lupus erythematosus (one [4%]), and dermohypodermitis (one [4%
133 n autoimmune diseases such as systemic lupus erythematosus or psoriasis, but pDCs are also involved i
135 ene expression is elevated in systemic lupus erythematosus patient cells, and systemic lupus erythema
137 on is increased in T cells of systemic lupus erythematosus patients and that this increased expressio
142 ctivity was assessed with the Systemic Lupus Erythematosus Pregnancy Disease Activity Index and the P
144 NKs purified from spleens of systemic lupus erythematosus-prone mice, and identified as NK1.1(+)CD11
145 ith type I diabetes mellitus, systemic lupus erythematosus, RA, and celiac disease, these results sug
146 n SJS/TEN and pre-existing depression, lupus erythematosus, recent pneumonia, chronic kidney disease,
147 ite responder indices such as Systemic Lupus Erythematosus Responder Index (SRI) and BILAG-based Comb
150 and future impact of AMDs on systemic lupus erythematosus, rheumatoid arthritis, and devastating mon
151 e autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclero
152 connective tissue disorders: systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis,
153 Basophils from patients with systemic lupus erythematosus show an activated phenotype, correlating t
154 h as rheumatoid arthritis and systemic lupus erythematosus, show a polygenic inheritance pattern.
156 rmine their associations with systemic lupus erythematosus (SLE) and clinical manifestations of SLE.
157 uently found in patients with systemic lupus erythematosus (SLE) and correlate with the occurrence of
158 aining serum from humans with systemic lupus erythematosus (SLE) and from a mouse model of SLE also i
159 deficiency is associated with systemic lupus erythematosus (SLE) and increased susceptibility to seve
161 3 is strongly associated with systemic lupus erythematosus (SLE) and many other autoimmune diseases.
162 is persistently activated in systemic lupus erythematosus (SLE) and many other systemic autoimmune d
167 -23 receptor in patients with systemic lupus erythematosus (SLE) as compared with healthy controls.
168 monocytes from children with systemic lupus erythematosus (SLE) behave similar to dendritic cells (D
169 the major IFNalpha source in systemic lupus erythematosus (SLE) but their phenotype and function in
172 T cells from patients with systemic lupus erythematosus (SLE) display a number of abnormalities, i
173 T cells from patients with systemic lupus erythematosus (SLE) exhibit reduced expression of the cr
175 he role of innate immunity in systemic lupus erythematosus (SLE) has been a rapidly expanding area of
177 r children born to women with systemic lupus erythematosus (SLE) have an increased risk of congenital
179 demonstrated that women with systemic lupus erythematosus (SLE) have fewer live births and more preg
180 autoimmune rheumatic disease systemic lupus erythematosus (SLE) have multiple defects in lymphocyte
209 sed studies have been done on systemic lupus erythematosus (SLE) mortality trends in the United State
213 was replicated in a cohort of systemic lupus erythematosus (SLE) patients (N = 47) and controls (N =
214 erived endothelial cells from systemic lupus erythematosus (SLE) patients expressed CD95L and that af
216 ndscape of naive B cells from Systemic Lupus Erythematosus (SLE) patients undergoing disease flares.
217 (+) B cells in nearly half of systemic lupus erythematosus (SLE) patients, and total numbers of ARID3
218 els of leptin are elevated in systemic lupus erythematosus (SLE) patients, but it is not clear whethe
221 n found to be associated with systemic lupus erythematosus (SLE) susceptibility by a recent genome-wi
222 NADPH oxidase (NADPHO), with systemic lupus erythematosus (SLE) susceptibility in individuals of Eur
223 f 39 variants associated with Systemic Lupus Erythematosus (SLE) through the integration of GWAS and
224 arge cohorts of patients with systemic lupus erythematosus (SLE) with and without LN and other glomer
225 flammatory diseases including systemic lupus erythematosus (SLE), Aicardi-Goutieres syndrome (AGS) an
226 /lpr mice, which are prone to systemic lupus erythematosus (SLE), and inhibited the antiviral immune
227 VID), Evans syndrome (ES), or systemic lupus erythematosus (SLE), and most achieved a CR (N = 8), alt
228 ted in the autoimmune disease systemic lupus erythematosus (SLE), but little is known about the pepti
229 locus is well established in systemic lupus erythematosus (SLE), but the causal functional variants
230 autoimmune diseases, such as systemic lupus erythematosus (SLE), but the natural history of autoreac
232 of autoimmunity, most notably systemic lupus erythematosus (SLE), diabetes mellitus, and dermatomyosi
233 Here we found that in human systemic lupus erythematosus (SLE), IgE antibodies specific for double-
235 S1, have been associated with systemic lupus erythematosus (SLE), or lupus, in independent cohorts of
236 utoimmune diseases, including systemic lupus erythematosus (SLE), Sjogren's syndrome, inflammatory bo
238 ome-wide association study of systemic lupus erythematosus (SLE), we observed a single risk haplotype
240 o autoimmune diseases such as systemic lupus erythematosus (SLE), where nucleic acid-containing immun
241 idal changes in patients with systemic lupus erythematosus (SLE), with or without glomerulonephritis;
243 ysM(Cre)Bim(fl/fl)) develop a systemic lupus erythematosus (SLE)-like disease that mirrors aged Bim(-
244 transferred bone marrow from systemic lupus erythematosus (SLE)-prone Sle123 mice into normal, ApoA-
281 reviously identified IgAN and systemic lupus erythematosus (SLE)/lupus nephritis (LN) shared many loc
282 associated with the risk for systemic lupus erythematosus (SLE); however, it is unclear how Ox40L co
283 inflammation associated with systemic lupus erythematosus (SLE); however, it remains unclear whether
285 of autoreactive IgE in human systemic lupus erythematosus subjects was also associated with increase
286 f autoimmune diseases such as systemic lupus erythematosus, thyroiditis, and rheumatic autoimmune dis
287 ing NMDA receptor function in systemic lupus erythematosus, traumatic brain injury, and Parkinson dis
289 Using an inducible model of systemic lupus erythematosus, we found that passive transfer of antinuc
290 with rheumatoid arthritis and systemic lupus erythematosus were demethylated compared to healthy cont
291 l of autoimmunity, similar to systemic lupus erythematosus, where both cell types are critical for di
292 crophages in diseases such as systemic lupus erythematosus, where impaired phagocytosis of apoptotic
293 ever, 1 participant developed systemic lupus erythematosus while on study and was excluded from furth
294 in the brain of patients with systemic lupus erythematosus with and without a history of central nerv
295 callosum of 13 patients with systemic lupus erythematosus with past NPSLE, 16 patients with systemic
297 re made between patients with systemic lupus erythematosus with/without past NPSLE and healthy contro
298 most severe manifestations of systemic lupus erythematosus, with considerable morbidity and mortality
299 utoimmune diseases, including systemic lupus erythematosus, with risk correlating with reduced expres
300 past NPSLE, 16 patients with systemic lupus erythematosus without past NPSLE, and 19 healthy control
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。